Nebenwirkungen · Nivestim
Nivestim 12 MU/0.2 ml solution for injection/infusion Nivestim 30 MU/0.5 ml solution for injection/infusion Nivestim 48 MU/0.5 ml solution for injection/infusion · Abschnitt 4.8 · PDF-Seite 13
HOS-122620 · Präparat HOS-095547
The most serious adverse reactions that may occur during filgrastim treatment include: anaphylactic reaction, serious pulmonary adverse events (including interstitial pneumonia and ARDS), capillary leak syndrome, severe splenomegaly/splenic rupture, transformation to myelodysplastic syndrome or leukaemia in SCN patients, GvHD in patients receiving allogeneic bone marrow transfer or peripheral blood cell progenitor cell transplant and sickle cell crisis in patients with sickle cell disease.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T16:00:00Z · SHA-256 5552b005274e22cefe547b04992e3848c41f1b5461a95fd2493f34858bdd5ae3 · Passage 92fcbb018686421c0db2b6f9dc539b8534c9d743ff73af2bad7b373287a4b50c · Zeichen 37–531 im Abschnitt